A previous study showed that SGLT-2 inhibitors can mimic the previously mentioned states by promoting catabolism, restoring mTOR cycling, and reducing cognitive impairment linked to metabolic disorders (Stanciu et al. 2021). This evidence concerns the gene MTOR and Cognitive impairment.